4783 T3D4728 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. 2907 C7H15Cl2N2O2P White powder. 48-49°C Soluble. 1-5 g/100 mL at 23°C After oral administration, peak concentrations occur at one hour. Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. Metabolism and activation occurs at the liver. 75% of the drug is activated by cytochrome P450 isoforms, CYP2A6, 2B6, 3A4, 3A5, 2C9, 2C18, and 2C19. The CYP2B6 isoform is the enzyme with the highest 4-hydroxylase activity. Cyclophosphamide undergoes activation to eventually form active metabolites, phosphoramide mustard and acrolein. Cyclophosphamide appears to induce its own metabolism which results in an overall increase in clearance, increased formation of 4-hydroxyl metabolites, and shortened t1/2 values following repeated administration. 1, carcinogenic to humans. (L135) Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients. Adverse reactions reported most often include neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea. 2014-09-11T05:13:41Z 2026-05-21T16:37:05Z Cyclophosphamide C07888 4027 DB00531 true ClCCN(CCCl)P1(=O)NCCCO1 C7H15Cl2N2O2P InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12) CMSMOCZEIVJLDB-UHFFFAOYSA-N 261.086 260.02481966 Exogenous Solid 0.8 CHEMBL88 2804 <p>Riccardo Dalla-Favera, Alessandro Massimo Gianni, &#8220;Retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs.&#8221; U.S. Patent US6268138, issued March, 1999.</p> CHEM003685 41.57 58.47810000000002 23.722394450622833 5 2 1 13.42654312142604 0.0840914699297235 0 1 0.76 -1.24 1.51e+01 g/l